Live healthier, stronger and sharper for longer
Short, frequent pieces on what changed in the science of ageing well — and our research library holds the deep dives.
PeptidesSS-31 (Elamipretide) & Longevity Biomarkers: Insights for 2026
This comprehensive analysis delves into SS-31 (Elamipretide)'s potential to influence critical longevity biomarkers, offering a nuanced perspective on its evidence base as of 2026.
PeptidesSS-31 (Elamipretide) & Longevity Biomarkers in 2026
SS-31 (Elamipretide) is often touted for its mitochondrial benefits. We scrutinise its influence on crucial longevity biomarkers, separating robust evidence from early signals.
PeptidesSS-31 (Elamipretide) & Longevity Biomarkers: Insights for 2026
SS-31 (Elamipretide) is a peptide targeting mitochondrial health. We dissect its influence on crucial longevity biomarkers, evaluating current evidence and future prospects for healthspan extension.
PeptidesSS-31 (Elamipretide) in 2026: Latest Clinical
A deep dive into SS-31 (Elamipretide)'s most recent clinical findings, focusing on 2025-2026 data and its implications for longevity and healthspan.
PeptidesSS-31 (Elamipretide): Latest Evidence and 2026
Explore the cutting-edge science behind SS-31 (Elamipretide), with a focus on breakthroughs from 2025-2026 and its potential in healthy ageing.
PeptidesSS-31 (Elamipretide) in 2026: Unpacking the
SS-31 (Elamipretide) continues to garner attention for its mitochondrial-targeting properties. We delve into the newest clinical data and revised insights for 2026.
PeptidesMOTS-c in the UK: 2026 Outlook for Availability
This deep dive examines the UK availability, legal standing, and cost considerations for MOTS-c, a promising mitochondrial-derived peptide, heading into 2026.
PeptidesSS-31 (Elamipretide) Insights: Latest Evidence
Discover the latest clinical findings for SS-31 (Elamipretide) in 2025-2026, focusing on mitochondrial health and its implications for longevity.
PeptidesSS-31 (Elamipretide) Latest Evidence 2026: A
This updated review focuses on the latest 2025-2026 evidence for SS-31 (Elamipretide), dissecting new clinical trials and their implications for longevity and mitochondrial health.
PeptidesSS-31 Dosing & Protocol Optimisation for
Demystifying SS-31 dosing is crucial for maximising its mitochondrial benefits. We break down protocols for longevity, performance, and recovery, informed by the latest research.
PeptidesOptimising SS-31 (Elamipretide) Dosing for
Understanding the nuanced dosing and protocol for SS-31 (Elamipretide) is paramount for maximising its mitochondrial-targeted benefits, from enhanced recovery to improved healthspan.
PeptidesSS-31 (Elamipretide) for Women: Optimising
SS-31 (Elamipretide) holds promise for optimising female healthspan by targeting mitochondrial dysfunction, particularly relevant through hormonal shifts and menopause.
PeptidesSS-31 (Elamipretide) After 50: Optimising
For those over 50, SS-31 (Elamipretide) offers a targeted approach to combating age-related mitochondrial decline, influencing sarcopenia, cognitive function, and overall vitality.
PeptidesSS-31 Stacks for Longevity in 2026: Optimal
SS-31, a potent mitochondrial peptide, shines brightest when combined thoughtfully. This guide explores optimal stacking strategies for enhanced longevity.
PeptidesMOTS-c for Sleep: Optimising Your Rest by 2026
Investigate how MOTS-c, a mitochondrial-derived peptide, could reshape sleep quality and circadian health. Learn about its mechanisms, benefits, and optimal usage.
PeptidesMOTS-c for Women: Hormonal Harmony &
MOTS-c, a mitochondrial peptide, offers significant potential for women's health, addressing hormonal fluctuations, metabolic shifts, and age-related decline.
PeptidesSS-31 (Elamipretide) Side Effects & Safety
A deep dive into the safety profile of SS-31 (Elamipretide), examining known side effects, potential interactions, and critical considerations for its use in 2026.
PeptidesMOTS-c Stacks for Longevity in 2026:
Discover how MOTS-c, a mitochondrial-derived peptide, can be synergistically stacked with other compounds to boost longevity efforts.
PeptidesSS-31 (Elamipretide) for Sleep in 2026: An
SS-31 (Elamipretide), a mitochondrial-targeting peptide, is gaining attention for its potential impact on sleep quality and circadian rhythm regulation.
PeptidesMOTS-c Peptide: 2026 Evidence and Revised
New 2025-2026 clinical data reshapes our understanding of the MOTS-c peptide. We analyse the latest evidence, updating efficacy, safety, and usage recommendations.
PeptidesMOTS-c for Cognition & Focus: A 2026
Could the mitochondrial peptide MOTS-c be a key player in enhancing cognition and focus by 2026? We dissect the latest research.
PeptidesSS-31 (Elamipretide) for Cognition in 2026: A
SS-31 (Elamipretide) is gaining attention for its cognitive benefits, primarily through mitochondrial support. This article examines its mechanisms and clinical data.
PeptidesMOTS-c Dosing Protocols for Healthspan
Precision MOTS-c dosing is key for maximising its metabolic benefits. Understand clinically studied ranges, titration, and cycling strategies.
Wondering where to start?
Two minutes, no blood test, no sign-up — find out how you are actually ageing, and what to do about it.
The Sunday briefing
One email a week: what changed in the evidence, what it means for the markers you track, and the occasional thing worth stopping. No spam, unsubscribe anytime.